KalVista Pharmaceuticals, Inc.: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2024)

-$183.4M

Total Assets (FY2024)

$250.8M

Total Equity (FY2024)

$95.4M

Cash Flows from Operating Activities (FY2024)

-$152.9M

Source: KalVista Pharmaceuticals, Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.